within Pharmacolibrary.Drugs.ATC.D;

model D05AX01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.2,
    Cl             = 50 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 120 / 1000000,
    adminCount     = 1,
    Vd             = 0.05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Fumaric acid is a naturally occurring organic acid that has been used as a medicinal product in the form of its ester derivatives (dimethyl fumarate or DMF) for the treatment of psoriasis and multiple sclerosis. Fumaric acid itself is generally not used directly as a pharmaceutical agent. The drug indicated by ATC code D05AX01 refers specifically to the fumarates used in dermatology, mainly for moderate to severe plaque psoriasis, and may include salts like calcium, magnesium, and zinc fumarate. Fumaric acid and its esters are approved in several European countries for psoriasis and DMF is approved globally for multiple sclerosis.</p><h4>Pharmacokinetics</h4><p>No direct human pharmacokinetic data available for fumaric acid as an isolated compound administered as a drug. Most pharmacokinetic studies pertain to its ester forms (i.e., dimethyl fumarate). Thus, below parameters are estimated or inferred.</p><h4>References</h4><ol><li><p>Rostami Yazdi, M, &amp; Mrowietz, U (2008). Fumaric acid esters. <i>Clinics in dermatology</i> 26(5) 522–526. DOI:<a href=&quot;https://doi.org/10.1016/j.clindermatol.2008.07.001&quot;>10.1016/j.clindermatol.2008.07.001</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18755371/&quot;>https://pubmed.ncbi.nlm.nih.gov/18755371</a></p></li><li><p>Mrowietz, U, et al., &amp; Clement, B (2018). The Pharmacokinetics of Fumaric Acid Esters Reveal Their In Vivo Effects. <i>Trends in pharmacological sciences</i> 39(1) 1–12. DOI:<a href=&quot;https://doi.org/10.1016/j.tips.2017.11.002&quot;>10.1016/j.tips.2017.11.002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29183628/&quot;>https://pubmed.ncbi.nlm.nih.gov/29183628</a></p></li><li><p>Shimizu, R, et al., &amp; Kubota, R (2022). Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults. <i>Antimicrobial agents and chemotherapy</i> 66(10) e0063222–None. DOI:<a href=&quot;https://doi.org/10.1128/aac.00632-22&quot;>10.1128/aac.00632-22</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36094202/&quot;>https://pubmed.ncbi.nlm.nih.gov/36094202</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end D05AX01;
